-
Research to Watch: Aumolertinib Delivers Notable Performance as an EGFR-Targeted Therapy in the Adjuvant Setting
Results from the phase III ARTS trial illustrate the potential of aumolertinib as adjuvant therapy for patients with resected EGFR-mutated NSCLC.
More Recent News
-
Leading by Example: A Message of Resilience, Gratitude, and Hope
During a special session at TTLC 2026, Dr. Ross Camidge shared his personal journey with lung cancer, discussing its impact on both his professional and personal life.
-
Personalized Lung Cancer Therapies: One Size Does Not Fit All
During the TTLC 2026 Opening Keynote, Dr. John V. Heymach said personalizing lung cancer therapies will require disentangling heterogeneity to understand the underlying factors driving the disease in each patient.